Plate Nº 16 · recorded October 30, 2026

Health & Medicine ResearchReported finding

Study of 16 children finds hidden aggressive cells in rhabdomyosarcoma

A study of 16 children found aggressive cells hidden inside some fusion-negative rhabdomyosarcomas, suggesting genetically different tumors can converge on the same dangerous biological state.

By Nathan Brooks5 min read953 words

In brief

  1. Researchers examined tumors from 16 children: four fusion-negative fatalities, four fusion-positive cases and eight surviving fusion-negative cases.
  2. About 55 children are diagnosed with rhabdomyosarcoma in the UK each year.
  3. Researchers used two methods, single-cell RNA sequencing and spatial transcriptomics, to identify shared aggressive cell states.
  4. The findings were reported on October 30, 2026, in Cancer Research.
  5. Scientists are expanding the study to hundreds of additional tumor samples.
Why some “lower-risk” childhood cancers turn deadly
Plate Nº 16Why some “lower-risk” childhood cancers turn deadly — Kost9n4 / pixabay

Four of 16 children in a 2026 study had rhabdomyosarcoma tumors that lacked the usual high-risk genetic marker yet proved fatal, pointing to aggressive cells hidden inside apparently lower-risk disease.

The Wellcome Sanger Institute reported the findings on October 30, 2026, in a paper published in Cancer Research. Scientists from the institute, the University of Cambridge, Great Ormond Street Hospital, University College London and collaborating institutions examined 16 tumor samples.

About 55 children are diagnosed with rhabdomyosarcoma in the United Kingdom each year. The aggressive cancer starts in muscle tissue and ranks among the most common soft-tissue cancers affecting children younger than 15.

Unlike many adult cancers, which can develop after years of aging or exposure to environmental factors, childhood cancers often result from genetic changes during early development.

Why did usual risk classification miss fatal tumors?

Doctors generally divide rhabdomyosarcoma into two risk categories based on a specific gene fusion. The PAX-FOXO1 marker appears when two normally separate genes join into an abnormal combination associated with especially aggressive disease.

Children with fusion-positive tumors have substantially lower survival rates than children without the fusion, even after intensive treatment. A 2013 Children's Oncology Group report by Skapek and colleagues had already linked fusion status to unfavorable outcomes (DOI: 10.1002/pbc.24532).

The 16-child comparison included:

  • Four children with fusion-negative tumors that proved fatal.
  • Four children with fusion-positive tumors.
  • Eight children with fusion-negative tumors who remained alive.

Those groups allowed researchers to look beyond the single marker used for risk assessment. The study asked whether fatal fusion-negative tumors shared biological features with high-risk disease.

How did one-cell analysis expose the hidden risk?

Researchers used single-cell RNA sequencing, which measures gene activity in individual cells rather than treating a tumor as one mass. They also used spatial transcriptomics, a method that maps gene activity to specific locations within tumor tissue.

Together, the methods showed that some tumors classified as non-high-risk contained cells with gene-activity patterns closely resembling those in high-risk tumors. Spatial mapping also revealed where those aggressive cells sat and how they were distributed.

The aggressive tumors did not require the same genetic mutations to behave similarly. Instead, researchers identified rare genetic changes affecting many of the same cellular pathways involved in the most dangerous disease. Different genetic abnormalities could therefore push cells toward one shared aggressive state.

Dr. Karin Straathof, co-senior author at University College London and Great Ormond Street Hospital, said: “Although these tumors carry different genetic changes, many converge on the same aggressive pathways. This helps explain why some children who appear to have lower-risk disease can still have a devastating outcome.”

Could this change diagnosis and treatment?

If doctors can identify distinctive biological signatures at diagnosis, they may recognize children facing greater risk of relapse or death even when standard genetic tests suggest otherwise. Such testing could also spare children with genuinely lower-risk tumors some harmful effects of intensive chemotherapy.

Children whose tumors conceal aggressive cells could instead receive stronger or more targeted treatment earlier. The researchers want to identify markers that can guide therapies aimed specifically at dangerous cancer cells. One possible route is immunotherapy, including CAR-T cell therapy, which uses specially modified immune cells to recognize and attack cancer cells.

The approach still needs development and testing in rhabdomyosarcoma. If researchers can validate the cell-state signatures and target them safely, CAR-T or other immune-based treatments could eventually provide a more precise alternative to chemotherapy and reduce damage to healthy tissue.

Sara Wakeling, chief executive officer and co-founder of Alice's Arc, said every child with cancer deserves the best possible chance of survival. She said the research shows how advanced technologies can reveal the biology behind aggressive childhood cancers and bring researchers closer to personalized treatment and better outcomes.

Dr. Laura Danielson, Children's and Young Person's Lead at Cancer Research UK, said discovery research is essential for understanding the unique biology of these cancers. She noted that aggressive tumors can share features despite different genetic changes, and that identifying common biology could guide future treatment efforts for children and young people.

What changes about risk classification?

The results suggest that doctors should consider the broader biological state of cancer cells, rather than relying mainly on the presence or absence of one genetic abnormality. Tumors with different mutations can behave in remarkably similar ways, making shared features a potentially more reliable warning sign.

Professor Sam Behjati, co-senior author formerly at the Wellcome Sanger Institute and head of the Department of Paediatrics at the University of Cambridge, said: “This work changes how we think about rhabdomyosarcoma. Rather than a single, abnormal gene, we've shown that there is an overarching cell state of aggressive disease that defies conventional classification systems.”

Understanding that shared state could help identify children who need more intensive treatment to improve survival. It could also spare children with genuinely lower-risk disease from treatment they may not need.

What must happen before clinics use these findings?

The findings do not yet change routine clinical care; the report says further research is needed. Scientists are expanding their work to include hundreds of additional tumor samples, aiming to uncover more rare genetic changes that produce aggressive disease and accelerate personalized treatments.

The study received a Cancer Research UK–Children with Cancer UK Innovation Award, with additional co-funding from Alice's Arc and funding from Wellcome. Holly J. Whitfield and colleagues published “High-Risk Rhabdomyosarcomas Feature a Convergent Cell State” in Cancer Research, volume 86, issue 19, page 4991. Its DOI is 10.1158/0008-5472.CAN-25-4403.

via childrenwithcancer.org.uk (Original)

Filed under

  • rhabdomyosarcoma
  • pediatric-cancer
  • single-cell-rna-sequencing
  • spatial-transcriptomics
  • cancer-genomics
Share this article:

More from Nathan Brooks

Nathan Brooks

Show full bio

Market editor covering companies, deals and strategy in general science news at SciBeat.

456 articles

Nearby plates

« Previous articleNext article »